ABMT Trials Unlikely To show Clean Benefit for Breast Cancer; Data Release Debated
In Brief: Stoval to Receive ACCC Award; Groopman, Sigal, Named to Board of Scientific Advisors
Drug Marketing; Zeneca sues Eli Lilly, Claiming Misleading Promotion of Evista
In Brief: NIH gives Advisors $50 Raise, Effective April 1, No Fooling
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ









